GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (NAS:GHSI) » Definitions » Enterprise Value

Guardion Health Sciences (Guardion Health Sciences) Enterprise Value : $7.27 Mil (As of Jun. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Guardion Health Sciences Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Guardion Health Sciences's Enterprise Value is $7.27 Mil. Guardion Health Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.50 Mil. Therefore, Guardion Health Sciences's EV-to-EBIT ratio for today is -2.08.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Guardion Health Sciences's Enterprise Value is $7.27 Mil. Guardion Health Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.48 Mil. Therefore, Guardion Health Sciences's EV-to-EBITDA ratio for today is -2.09.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Guardion Health Sciences's Enterprise Value is $7.27 Mil. Guardion Health Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $12.06 Mil. Therefore, Guardion Health Sciences's EV-to-Revenue ratio for today is 0.60.


Guardion Health Sciences Enterprise Value Historical Data

The historical data trend for Guardion Health Sciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardion Health Sciences Enterprise Value Chart

Guardion Health Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only 5.99 29.69 6.74 3.79 0.45

Guardion Health Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 1.49 1.75 0.45 5.98

Competitive Comparison of Guardion Health Sciences's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardion Health Sciences's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's Enterprise Value falls into.



Guardion Health Sciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Guardion Health Sciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Guardion Health Sciences's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardion Health Sciences  (NAS:GHSI) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Guardion Health Sciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=7.273/-3.499
=-2.08

Guardion Health Sciences's current Enterprise Value is $7.27 Mil.
Guardion Health Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.50 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Guardion Health Sciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=7.273/-3.479
=-2.09

Guardion Health Sciences's current Enterprise Value is $7.27 Mil.
Guardion Health Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.48 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Guardion Health Sciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=7.273/12.063
=0.60

Guardion Health Sciences's current Enterprise Value is $7.27 Mil.
Guardion Health Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardion Health Sciences Enterprise Value Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardion Health Sciences (Guardion Health Sciences) Business Description

Traded in Other Exchanges
Address
2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098
Guardion Health Sciences Inc is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product. The company's Medical Foods include Lumega-Z and GlaucoCetin; Medical Devices include Mapcat SF, VectorVision, CSV-1000 and CSV-2000; Nutraceuticals include ImmuneSF.
Executives
Katharine Joan Cox officer: Chief Accounting Officer 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Janet Hall officer: CEO & President 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bradley Louis Radoff 10 percent owner 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Family Foundation Radoff other: See Footnote 1 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Michaela Griggs director 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bret Scholtes director, officer: Chief Executive Officer 2105 CITY WEST BLVD., SUITE 500, HOUSTON TX 77042
Donald A Gagliano director 131 CARDINAL AVE, SAN ANTONIO TX 78209
Jeffrey S Benjamin officer: Chief Accounting Officer 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
Craig Sheehan officer: Chief Commercial Officer 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
David W Evans director, officer: Chief Scientific Officer 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Tamara A Evans 10 percent owner 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Vincent J Roth officer: General Counsel and Secretary 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Robert N Weingarten director 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Guardion Health Sciences (Guardion Health Sciences) Headlines

From GuruFocus